Avelumab and Merkel Cell Carcinoma: Evaluating Causation

From General Health Communication to Occupational Exposure Concerns

The legacy of general health and science communication has long emphasized broad wellness principles, disease prevention, and the interpretation of medical research for public understanding. Within this framework, discussions of pharmaceutical interventions typically focus on therapeutic benefits and common side effects, framed within a population-level risk-benefit analysis. This heritage provides a foundation for evaluating how specific medications interact with disease processes, yet it often abstracts away from the granular details of individual exposure scenarios. Transitioning from this general context, the focus now narrows to a specific occupational exposure concern: the relationship between Avelumab, a monoclonal antibody used in oncology, and the risk of Merkel Cell Carcinoma. In occupational settings, particularly for healthcare workers, researchers, or pharmaceutical manufacturing personnel, the potential for unintended exposure to such biologic agents raises distinct questions. Unlike the patient-centered perspective of therapeutic use, occupational exposure involves chronic, low-level contact that may not mirror clinical dosing regimens. This pivot requires examining whether Avelumab exposure—through handling, administration, or environmental contamination—could plausibly influence Merkel Cell Carcinoma risk, distinct from its intended mechanism of action. The shift from general health literacy to this specific occupational hazard underscores the need for targeted risk assessment, moving beyond broad educational messaging to address the unique vulnerabilities of those in direct contact with these agents.

Clinical and Pharmacological Context of Avelumab and Merkel Cell Carcinoma

Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is characterized by rapid growth and a high propensity for metastasis. MCC is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). Diagnosis typically involves histopathological examination of a biopsy specimen, with immunohistochemical staining for neuroendocrine markers such as cytokeratin 20 and chromogranin A. Clinical presentation often includes a painless, firm, red or purple nodule on sun-exposed skin, though lesions can occur anywhere. Given its aggressive nature, prompt diagnosis and staging are critical. Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It functions as an immune checkpoint inhibitor, blocking the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby enhancing the immune system's ability to attack cancer cells. Avelumab is approved in the USA, the EU, and Japan for the treatment of metastatic MCC, making it the first therapeutic agent specifically approved for this indication (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the JAVELIN Merkel 200 trial, a two-part, single-arm, phase II study in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Reported adverse effects of avelumab include immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). These can range from mild to severe and may involve various organ systems. For example, a case of hypercalcaemia secondary to reactivation of sarcoidosis during avelumab treatment for metastatic MCC has been reported, which was managed with corticosteroids and allowed continuation of avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other common irAEs include dermatitis, colitis, hepatitis, pneumonitis, and endocrinopathies. The risk of such events is inherent to the mechanism of immune checkpoint inhibition.

Mechanistic Pathways and Evidence for Causation

The query asks whether avelumab causes MCC. The evidence indicates that avelumab is a treatment for MCC, not a cause. Mechanistically, avelumab is designed to treat MCC by blocking PD-L1, which is often expressed on MCC tumor cells, thereby restoring T-cell-mediated antitumor immunity. The drug's efficacy in MCC is well-documented, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). There is no evidence in the provided snippets suggesting that avelumab induces or causes MCC. Instead, the drug is used to manage the disease. The only reported adverse events are immune-related, which are a consequence of its mechanism of action and not indicative of carcinogenesis. Given that avelumab is approved specifically for the treatment of MCC, warnings about the drug focus on its therapeutic use and potential adverse effects, not on causation of the disease. The evidence does not indicate any inadequacy in warnings, as the drug's labeling appropriately describes its indication for MCC and its known irAEs. For example, the case of sarcoidosis reactivation was managed without discontinuing avelumab, suggesting that clinicians are aware of and can manage such events (https://pubmed.ncbi.nlm.nih.gov/31543781/). The risk of progression on therapy is also acknowledged, with approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progressing on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For avelumab-refractory patients, alternative treatments such as ipilimumab plus nivolumab have been studied (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/).

Causation-Related Considerations for Affected Patients

For patients with MCC, the question of causation is irrelevant in the context of avelumab, as the drug is a treatment, not a cause. However, patients may be concerned about whether avelumab could worsen their disease or cause new cancers. The evidence does not support such concerns. Instead, avelumab has demonstrated clinical benefit in a subset of patients. For those who do not respond or become refractory, the disease itself is aggressive, and progression is a known risk of MCC rather than a drug effect. The timeline between exposure and harm is therefore related to disease progression or the onset of irAEs, which typically occur during treatment and are manageable. The evidence does not document a causal timeline between avelumab exposure and the development of MCC. Instead, the timeline of interest is between avelumab treatment and therapeutic response or adverse events. In the JAVELIN Merkel 200 trial, responses were observed during treatment, and irAEs such as sarcoidosis reactivation occurred during therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who progress on avelumab, the timeline reflects the natural history of refractory MCC rather than drug-induced harm. The studies on avelumab-refractory patients show that subsequent treatment with ipilimumab plus nivolumab can be effective, further supporting that avelumab does not cause MCC but rather is used to treat it (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/).

Conclusion

Based on the provided evidence, avelumab does not cause Merkel cell carcinoma. It is an approved and effective treatment for metastatic MCC, with a well-characterized safety profile that includes immune-related adverse events. Warnings about the drug appropriately address its therapeutic use and potential side effects. For affected patients, the focus should be on managing the disease and treatment-related adverse events, with no evidence to suggest that avelumab induces MCC.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does Avelumab cause Merkel Cell Carcinoma?

No, Avelumab is a treatment for Merkel Cell Carcinoma, not a cause. It is an immune checkpoint inhibitor approved for metastatic MCC and works by blocking PD-L1 to enhance antitumor immunity. There is no evidence that Avelumab induces MCC.

What are the side effects of Avelumab?

Avelumab can cause immune-related adverse events (irAEs) such as dermatitis, colitis, hepatitis, pneumonitis, endocrinopathies, and reactivation of conditions like sarcoidosis (https://pubmed.ncbi.nlm.nih.gov/31543781/). These are manageable and not indicative of carcinogenesis.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.